Hasan SENOLCOSKUN, Melek Karakurt ERYİLMAZ, Gokhan TAZEGUL, Derya Kivrak SALİM, Fatma Yalcin MUSRİ, Hasan MUTLU

Glossodynia induced by panitumumab in metastatic colorectal cancer: report of two cases

Kolorektal kanser en sık üçüncü kanserdir ve hem erkek hem de kadınlarda kansere bağlı ölümün üçüncü en sık sebebidir. Yeni tanı alan hastaların neredeyse %20'sinde tanı anında uzak saha metastazları mevcuttur. Panitumumab tam insan IgG2 monoklonal antikoru olup epidermal büyüme faktörü reseptörünü (EGFR) hedefler, metastatik kolorektal kanser (mKRK) tedavisinde sıklıkla kullanılmaktadır. Panitumumab'ın irinotekan ve oksaliplatin bazlı tedavi rejimleri ile kombinasyonları wild tip RAS tümörlerde hem ilk hem de ikinci basamakta makul seçimlerdir. Bununla birlikte, panitimumab ile papülopüstüler akneiform döküntü, hipomagnezemi ve diyare gibi yan etkiler bildirilmiştir. Daha önce panitumumab ile stomatit olmaksızın dil ağrısı vakası bildirilmemiştir. Bu vakada, mKRK için panitumumab alan iki hastada gelişen dil ağrısı sunulmaktadır

Metastatik kolorektal kanserde panitumumab'a bağlı dil ağrısı: iki vaka takdimi

Colorectal cancer (CRC) is the third most common cancer, and is the third most common cause of death due to cancer in both women and men.Approximately 20 percent of patients with newly diagnosed colon cancer have distant metastatic disease at the time of diagnosis. Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and it is commonly used to treat metastatic colorectal cancer (mCRC). Combinations of panitumumab plus an irinotecan or oxaliplatin-based regimen are reasonable both first-line and second-line options for mCRC with RAS wild type tumors. However, it has been associated with various side effects such as papulopustular acneiform rash, hypomagnesemia, and diarrhea. No previous reports on patients who developed tongue pain without stomatitis while treatment with panitumumab exists in the literature. Here we report two cases that developed tongue pain while on panitumumab for mCRC

PDF

___

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5-29.
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134(5):1296-310.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64.
Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer 2011;10(4):333-9.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-705.
Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58(3):984-90.
Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati Get al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer 2015;51(13):1704-13.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first- line treatment of metastatic colorectal cancer. Ann Oncol 2014;25(7):1346-55.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34.
Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M,et al. Analysis of KRAS/NRAS Mutations in a Phase 3 Study of Panitumumab With FOLFIRI Compared With FOLFIRI Alone as Second-Line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res 2015;21(24):5469-79.
Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C,et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015;51(5):587-94.
Bergman H, Walton T, Del Bel R, , Seki JT, Rafii A, Xu W, et al. Managing skin toxicities related to panitumumab. J Am Acad Dermatol 2014;71(4):754-9.
Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti- epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6(1):29-31.
Petrelli F, Cabiddu M, Borgonovo K, Barni S.Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23(7):1672-9.
Terai H, Shimahara M. Tongue pain: burning mouth syndrome vs Candida- associated lesion. Oral Dis 2007;13(4):440-2.
Mock D, Chugh D. Burning mouth syndrome. Int J Oral Sci 2010;2(1):1-4.
Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Candidiasis may induce glossodynia without objective manifestation. Am J Med Sci 2000;319(2):100-5.
Terai H, Shimahara M. Glossodynia from Candida- associated lesions, burning mouth syndrome, or mixed causes. Pain Med 2010;11(6):856-60.
Yoshida H, Tsuji K, Sakata T, Nakagawa A, Morita S. Clinical study of tongue pain: Serum zinc, vitamin B12, folic acid, and copper concentrations, and systemic disease. Br J Oral Maxillofac Surg 2010;48(6):469-72.
Cho GS, Han MW, Lee B, Roh JL, Choi SH, Cho KJ. Zinc deficiency may be a cause of burning mouth syndrome as zinc replacement therapy has therapeutic effects. J Oral Pathol Med 2010;39(9):722-7.